Welcome to our dedicated page for PACS Group SEC filings (Ticker: PACS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The PACS Group, Inc. (NYSE: PACS) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, along with AI-powered summaries to help interpret them. As a healthcare holding company in the post-acute care and medical care facilities space, PACS uses SEC reports to describe its facility portfolio, credit arrangements, governance, and risk profile.
Investors can review annual reports on Form 10-K and quarterly reports on Form 10-Q for detailed discussions of PACS Group’s operations, financial condition, and risk factors. These filings also provide context on the company’s role as a holding company, the structure of its independent operating subsidiaries, and the separation between licensed healthcare providers and non-provider entities. AI-generated highlights can point out key sections on post-acute care operations, use of credit facilities, and lease obligations.
Current reports on Form 8-K are particularly important for PACS, given its history of restatements, credit agreement amendments, and NYSE listing updates. Recent 8-K filings have addressed topics such as forbearance and amendments under the company’s amended and restated credit agreement, events of default and related waivers, NYSE listing extensions tied to delayed SEC filings, and the completion of an independent Audit Committee investigation and related restatements. AI summaries can help users quickly understand the implications of these events.
Users can also access proxy materials such as the Definitive Proxy Statement on Schedule 14A, which outlines matters presented to stockholders at the annual meeting, including director elections, auditor ratification, and advisory votes on executive compensation. In addition, the filings page provides real-time updates from EDGAR and convenient access to other forms, such as notifications of late filings on Form 12b-25. Together, these documents offer a comprehensive view of PACS Group’s regulatory history, governance decisions, and financial reporting, with AI tools available to simplify and explain complex disclosures.
PACS Group, Inc. reported that its Chief Legal Officer and Secretary received new equity awards in the form of restricted stock units (RSUs). On 12/17/2025, the officer acquired 100,000 shares of common stock at a price of $0 and an additional 21,855 shares at a price of $0, both reported as RSU grants. One RSU award vests in substantially equal annual installments on the first, second, and third anniversaries of January 15, 2025, and the other vests in substantially equal annual installments on the first, second, and third anniversaries of November 25, 2025, in each case subject to continued service. Following these transactions, the officer beneficially owns 877,691 shares of common stock directly.
PACS Group, Inc. reported an insider equity award for its President & Chief Operating Officer. On December 17, 2025, the executive received 175,000 shares of common stock in the form of restricted stock units (RSUs) at a price of $0. These RSUs vest in three substantially equal annual installments on the first, second, and third anniversaries of January 15, 2025, contingent on continued service.
On the same date, the executive also received an additional 41,018 RSUs at $0, vesting in three substantially equal annual installments on the first, second, and third anniversaries of November 25, 2025, also subject to continued service. Following these equity grants, the executive beneficially owns 2,725,680 shares of PACS Group common stock directly.
PACS Group, Inc. insider and co-founder, who serves as interim CFO and executive vice chair and is also a director and 10% owner, reported new equity awards in the form of restricted stock units (RSUs). On 12/17/2025, the insider was granted 150,000 RSUs of common stock at a price of $0, and a separate grant of 41,018 RSUs of common stock, also at $0. After these awards, the insider beneficially owned 54,817,217 shares of common stock.
The 150,000 RSUs will vest in substantially equal annual installments on the first, second, and third anniversaries of January 15, 2025, subject to continued service. The 41,018 RSUs will vest in substantially equal annual installments on the first, second, and third anniversaries of November 25, 2025, also subject to continued service. Each RSU converts into one share of common stock upon vesting, so these grants increase the insider’s future equity exposure to PACS Group, Inc. over the multi‑year vesting period.
PACS Group, Inc. reported an insider equity award for its Co-Founder, CEO, Chairman and director, who is also a 10% owner. On December 17, 2025, the reporting person acquired 200,000 shares of common stock through restricted stock units and an additional 41,018 restricted stock units, both at a price of $0 per share.
The 200,000 RSUs vest in substantially equal annual installments on the first, second and third anniversaries of January 15, 2025, while the 41,018 RSUs vest in substantially equal annual installments on the first, second and third anniversaries of November 25, 2025, in each case subject to continued service. Following these transactions, the reporting person beneficially owns 54,867,217 shares of PACS Group common stock directly.
PACS Group, Inc. reported that it entered into a Sixth Amendment to its Amended and Restated Credit Agreement with Truist Bank and its lenders on November 26, 2025. This amendment waives all previously identified defaults and events of default under the credit facility that had been disclosed in a forbearance agreement dated October 21, 2025.
The amendment also adjusts a key financial covenant so that the requirement to maintain at least
PACS Group, Inc. director share purchase disclosed
A director of PACS Group, Inc. (PACS) reported buying common stock in an open-market transaction. On 11/24/2025, the reporting person purchased 16,724 shares of PACS common stock at a weighted average price of $29.897 per share, with individual trades executed between $29.59 and $30.16. After this transaction, the director beneficially owned 22,739 shares directly. The filing notes that detailed trade-by-trade pricing information within this range is available upon request.
PACS Group, Inc. officer reports sale of common stock
A PACS Group, Inc. officer, serving as Chief Legal Officer and Secretary, reported selling 159,556 shares of PACS common stock on 11/24/2025. The transaction was coded "S," indicating an open-market or private sale. The weighted average sale price was $29.8853 per share, with individual trades executed between $29.54 and $30.125 per share. Following this sale, the officer beneficially owns 755,836 PACS common shares directly.
The filer notes a willingness to provide details on the number of shares sold at each individual price within the reported range upon request.
PACS Group, Inc. is asking stockholders to vote at its fully virtual 2025 Annual Meeting on December 19, 2025. Holders of common stock as of the November 10, 2025 record date, when 156,615,444 shares were outstanding, are entitled to one vote per share.
Stockholders will vote on electing two Class I directors (Taylor Leavitt and Jacqueline Millard) to terms ending at the 2028 meeting, ratifying Ernst & Young LLP as independent auditor for 2025, choosing how often to hold future say‑on‑pay votes (the Board recommends every one year), and approving on an advisory basis the 2024 compensation of named executive officers.
The Board highlights that PACS is a NYSE “controlled company,” with co‑founders Jason Murray and Mark Hancock collectively holding about 70% of voting power and possessing board designation rights. The proxy also describes board committee structures, independence determinations, risk oversight, and a shift in 2024 to more market‑standard executive pay practices, including an Adjusted EBITDA‑based bonus plan, new RSU grants with five‑year vesting, and a severance plan for executives.
A holder of PACS common stock filed a Form 144 notice to sell 159,556 shares through J.P. Morgan Securities LLC on or about 11/24/2025 on NASDAQ. The shares have an aggregate market value of 4,387,790 and are part of a larger base of 156,615,144 shares outstanding. The securities to be sold were acquired from the issuer on 04/15/2024 through an RSU vesting transaction for the same number of shares.
PACS Group, Inc. reported that it has released its financial results for the period ended September 30, 2024. The company furnished a press release as an exhibit to this current report, rather than formally filing the detailed results in the body of the report itself. This means the main financial and operating figures are contained in the accompanying press release referenced as Exhibit 99.1.
FAQ
What is the current stock price of PACS Group (PACS)?
What is the market cap of PACS Group (PACS)?
